Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

REPL

Replimune Group Inc

Feb 06 • 04:00PM ET

14.06

Dollar change -0.19
Percentage change -1.33	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX FATE SGMO KPTI ALVR PGEN ADAP ANIX ENTX

| Held by: VTI IWM XBI VXF IWN IBB SCHA VTWO DFAS FESM

Index	RUT	P/E	-	EPS (ttm)	-3.12	Insider Own	18.55%	Shs Outstand	68.39M	Perf Week	3.23%
Market Cap	1.06B	Forward P/E	-	EPS next Y	-2.40	Insider Trans	-0.22%	Shs Float	61.36M	Perf Month	16.97%
Income	-213.02M	PEG	-	EPS next Q	-0.71	Inst Own	81.64%	Short Float	11.83%	Perf Quarter	16.97%
Sales	0.00M	P/S	-	EPS this Y	15.48%	Inst Trans	-3.13%	Short Ratio	7.99	Perf Half Y	43.76%
Book/sh	5.58	P/B	2.52	EPS next Y	12.24%	ROA	-40.17%	Short Interest	7.26M	Perf Year	99.43%
Cash/sh	5.73	P/C	2.45	EPS next 5Y	13.46%	ROE	-50.32%	52W Range	4.92 - 17.00	Perf YTD	16.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-19.52%	ROI	-46.96%	52W High	-17.29%	Beta	1.29
Dividend TTM	-	Quick Ratio	10.11	Sales past 5Y	0.00%	Gross Margin	-	52W Low	185.77%	ATR (14)	0.92
Dividend Ex-Date	-	Current Ratio	10.11	EPS Y/Y TTM	2.71%	Oper. Margin	-	RSI (14)	61.59	Volatility	5.14% 7.93%
Employees	331	Debt/Eq	0.20	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.12	Target Price	20.50
Option/Short	Yes / Yes	LT Debt/Eq	0.19	EPS Q/Q	25.12%	Payout	-	Rel Volume	0.53	Prev Close	14.25
Sales Surprise	-	EPS Surprise	17.41%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	908.27K	Price	14.06
SMA20	11.36%	SMA50	10.68%	SMA200	36.47%	Trades		Volume	483,436	Change	-1.33%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Initiated	ROTH MKM	Buy	$17
Apr-17-23	Resumed	Piper Sandler	Overweight	$44
Nov-19-21	Initiated	Piper Sandler	Overweight	$52
Oct-15-21	Resumed	BTIG Research	Buy	$60
Nov-17-20	Initiated	BTIG Research	Buy	$60
Nov-02-20	Initiated	Jefferies	Buy	$67
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy	$25 → $54
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral	$25
May-05-20	Initiated	Barclays	Overweight	$21
Sep-04-19	Initiated	ROTH Capital	Buy	$20
Jul-23-19	Initiated	Chardan Capital Markets	Buy	$28
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight	$27 → $26
Jul-08-19	Initiated	H.C. Wainwright	Buy	$26
Apr-25-19	Initiated	Wedbush	Outperform	$24
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	Leerink Partners	Outperform	$25
Aug-14-18	Initiated	JP Morgan	Overweight	$26

Show Previous Ratings

Jan-23-25 07:06AM	Replimune price target raised to $21 from $17 at H.C. Wainwright (TipRanks) +5.61%
Jan-21-25 01:01PM	Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy (GuruFocus.com) +16.86%
08:00AM	Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma (GlobeNewswire)
Jan-10-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-25 08:00AM	Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials (GlobeNewswire)
08:00AM	Loading…
Dec-23-24 08:00AM	Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-25-24 11:55PM	Replimune Announces Pricing of Upsized Public Offering (GlobeNewswire) -11.19% +8.45%
07:09AM	Replimune Announces Proposed Public Offering (GlobeNewswire)
Nov-22-24 04:00PM	S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results (Benzinga) +35.11%
05:48AM	Replimune's stock surges 19% after-hours on FDA BLA submission (Investing.com)
Nov-21-24 04:05PM	Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway (GlobeNewswire)
Nov-12-24 08:00AM	Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-09-24 01:00PM	Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) (GlobeNewswire)
Nov-08-24 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-24 09:15AM	Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
04:01PM	Loading…
Oct-09-24 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.60%
Oct-07-24 09:11PM	Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings (GuruFocus.com)
Oct-01-24 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.58%
Sep-15-24 09:45AM	Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-09-24 08:00AM	Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024 (GlobeNewswire)
Sep-05-24 08:00AM	Stockholders Vote to Elect Madhavan Balachandran to Board of Directors (GlobeNewswire)
Aug-22-24 08:00AM	Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Aug-14-24 04:33PM	Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy (Pharmaceutical Technology)
Aug-13-24 08:00AM	Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma (GlobeNewswire)
Aug-08-24 08:00AM	Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-30-24 04:01PM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Jun-13-24 08:30AM	Replimune Announces $100 Million Private Placement Financing (GlobeNewswire) +7.26%
Jun-07-24 09:03AM	Replimune (REPL) Gains on Positive Data From Melanoma Study (Zacks) +11.11%
08:00AM	Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-06-24 12:16PM	Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? (Benzinga) +27.88%
07:00AM	Loading…
07:00AM	Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma (GlobeNewswire)
Jun-03-24 08:00AM	Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-23-24 05:00PM	Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.77%
May-16-24 01:53PM	REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024 (InvestorPlace)
08:00AM	Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-07-24 05:00PM	Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Apr-04-24 08:00AM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-26-24 07:30AM	Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions (GlobeNewswire)
Mar-11-24 09:55AM	How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17% (Zacks)
Mar-08-24 12:00PM	What Makes Replimune Group, Inc. (REPL) a New Buy Stock (Zacks)
Mar-06-24 08:00AM	Replimune to Present at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-05-24 08:00AM	Replimune to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Feb-23-24 09:55AM	Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High? (Zacks)
Feb-08-24 08:42AM	Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway (GuruFocus.com)
08:00AM	Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-16-24 03:59AM	DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing (PR Newswire) -5.55%
Dec-28-23 08:00AM	Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-23 07:32AM	UPDATE 1-Replimune's skin cancer drug fails in mid-stage study (Reuters) -45.21%
07:10AM	CORRECTED-Replimune's skin cancer drug fails in mid-stage study (Reuters)
07:00AM	Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers (GlobeNewswire)
Nov-13-23 09:55AM	Forbion co-leads 129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 (GlobeNewswire)
Nov-08-23 09:10AM	Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research (GlobeNewswire) +6.56%
Nov-07-23 08:00AM	Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -15.85%
Nov-03-23 07:30PM	Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) -9.37%
Oct-17-23 03:00AM	Tessellate BIO Emerges from Stealth (GlobeNewswire)
Sep-19-23 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.79%
08:00AM	Replimune Announces Appointment of Emily Hill as Chief Financial Officer (GlobeNewswire)
Sep-14-23 01:23PM	Insider Sell: Pamela Esposito Sells 5,658 Shares of Replimune Group Inc (GuruFocus.com)
Aug-03-23 08:00AM	Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.69%
Aug-01-23 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Jul-31-23 04:01PM	Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma (Business Wire)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Jul-20-23 08:00AM	Replimune Announces Sander Slootweg will Depart from its Board of Directors (GlobeNewswire) -5.44%
Jun-06-23 10:00AM	Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting (GlobeNewswire)
Jun-05-23 08:00AM	Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors (GlobeNewswire) +19.01%
Jun-03-23 02:15PM	Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Jun-01-23 04:01PM	Replimune to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-25-23 05:00PM	Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-18-23 08:00AM	Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-17-23 10:02AM	Is a Surprise Coming for Replimune (REPL) This Earnings Season? (Zacks) +5.46%
May-09-23 08:00AM	Replimune to Participate in the Piper Sandler Spring Biopharma Symposium (GlobeNewswire)
Mar-31-23 09:35AM	Down -22% in 4 Weeks, Here's Why Replimune Group, Inc. (REPL) Looks Ripe for a Turnaround (Zacks)
Mar-08-23 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Feb-24-23 09:35AM	Replimune Group, Inc. (REPL) Loses -14.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -11.29%
Feb-09-23 08:50AM	Replimune Group, Inc. (REPL) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) -9.12%
08:00AM	Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-07-23 08:00AM	Replimune to Present at the Virtual SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-06-23 09:55AM	Wall Street Analysts Think Replimune Group, Inc. (REPL) Could Surge 87.88%: Read This Before Placing a Bet (Zacks)
09:04AM	Institutional investors may adopt severe steps after Replimune Group, Inc.'s (NASDAQ:REPL) latest 5.3% drop adds to a year losses (Simply Wall St.)
08:50AM	Recent Price Trend in Replimune Group, Inc. (REPL) is Your Friend, Here's Why (Zacks)
Jan-05-23 05:44AM	The Petri Dish: Fulcrum CEO steps down; Moderna cools on mpox vaccine (American City Business Journals)
Jan-04-23 08:05AM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer (GlobeNewswire)
Jan-03-23 08:00AM	Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-14-22 10:46AM	Replimune Breaks Out: Could Rise 30% From Here (TheStreet.com) +5.76%
Dec-12-22 02:36PM	Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform (Benzinga)
Dec-08-22 09:04PM	Replimune Announces Pricing of Public Offering (GlobeNewswire)
Dec-07-22 04:04PM	Replimune Announces Proposed Public Offering (GlobeNewswire) +22.23%
10:05AM	Replimune Shares Surge After Early Data From Pretreated Melanoma Patients (Benzinga)
07:00AM	Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update (GlobeNewswire)
06:30AM	Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma (GlobeNewswire)
Nov-23-22 08:00AM	Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-22-22 08:00AM	Replimune to Host Virtual Investor Event on December 7, 2022 (GlobeNewswire) +5.14%
Nov-03-22 08:00AM	Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 04:01PM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Oct-14-22 01:52PM	Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts (Benzinga) +5.13%
Oct-07-22 08:00AM	Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. (GlobeNewswire)
Aug-24-22 07:58AM	Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks (Motley Fool)

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Sushil	Chief Executive Officer	Dec 16 '24	Sale	12.42	10,000	124,200	202,014	Dec 18 09:00 PM
Sushil Patel	Chief Strategy Officer	Dec 16 '24	Proposed Sale	12.57	15,000	188,550		Dec 16 04:48 PM
Xynos Konstantinos	Chief Medical Officer	Nov 18 '24	Sale	10.78	7,246	78,112	109,885	Nov 20 09:31 PM
Sarchi Christopher	Chief Commercial Officer	Nov 18 '24	Sale	10.78	5,207	56,131	87,045	Nov 20 09:30 PM
Hill Emily Luisa	Chief Financial Officer	Aug 16 '24	Sale	10.18	8,938	90,989	101,057	Aug 19 08:00 PM
Xynos Konstantinos	Chief Medical Officer	Jun 07 '24	Sale	7.50	15,881	119,108	117,131	Jun 10 08:30 PM
Sarchi Christopher	Chief Commercial Officer	May 16 '24	Sale	6.47	2,218	14,350	92,252	May 20 08:06 PM
Schwendenman Andrew	Chief Accounting Officer	May 16 '24	Sale	6.47	2,298	14,868	38,238	May 20 08:06 PM
Love Colin	Chief Operating Officer	May 16 '24	Sale	6.47	17,615	113,969	777,345	May 20 08:05 PM
Astley-Sparke Philip	Executive Chairman	May 16 '24	Sale	6.47	37,928	245,394	1,487,350	May 20 08:04 PM
Coffin Robert	Director	May 16 '24	Sale	6.47	11,464	74,172	1,821,872	May 20 08:02 PM
Patel Sushil	Chief Executive Officer	May 16 '24	Sale	6.47	20,194	130,655	212,014	May 20 08:01 PM
Xynos Konstantinos	Chief Medical Officer	May 16 '24	Sale	6.47	6,367	41,194	133,012	May 20 08:00 PM

Open in Screener

RVMD

Revolution Medicines Inc

Feb 06 • 04:00PM ET

43.57

Dollar change -0.68
Percentage change -1.54	%

Healthcare • Biotechnology • USA • NASD

RVMD Revolution Medicines Inc daily Stock Chart

Peers: AMGN GILD VRTX BMY MRNA PFE REGN ILMN BIIB EXEL

| Held by: VTI IWM VB VXF VBK XBI IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-3.59	Insider Own	15.52%	Shs Outstand	167.75M	Perf Week	1.16%
Market Cap	7.94B	Forward P/E	-	EPS next Y	-3.96	Insider Trans	3.63%	Shs Float	154.04M	Perf Month	-0.62%
Income	-567.06M	PEG	-	EPS next Q	-0.99	Inst Own	82.16%	Short Float	10.77%	Perf Quarter	-22.02%
Sales	0.74M	P/S	10736.46	EPS this Y	10.03%	Inst Trans	1.53%	Short Ratio	10.39	Perf Half Y	0.65%
Book/sh	9.34	P/B	4.67	EPS next Y	-13.97%	ROA	-41.28%	Short Interest	16.59M	Perf Year	44.80%
Cash/sh	8.50	P/C	5.13	EPS next 5Y	-2.74%	ROE	-47.18%	52W Range	28.43 - 62.40	Perf YTD	-0.39%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-36.05%	ROI	-34.48%	52W High	-30.18%	Beta	1.45
Dividend TTM	-	Quick Ratio	14.24	Sales past 5Y	-23.15%	Gross Margin	-1420.89%	52W Low	53.25%	ATR (14)	1.63
Dividend Ex-Date	-	Current Ratio	14.24	EPS Y/Y TTM	-10.04%	Oper. Margin	-88031.94%	RSI (14)	53.37	Volatility	3.40% 3.98%
Employees	378	Debt/Eq	0.06	Sales Y/Y TTM	-97.16%	Profit Margin	-76423.32%	Recom	1.07	Target Price	73.29
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	5.64%	Payout	-	Rel Volume	1.12	Prev Close	44.25
Sales Surprise	-100.00%	EPS Surprise	-5.24%	Sales Q/Q	-	Earnings	Nov 06 AMC	Avg Volume	1.60M	Price	43.57
SMA20	4.63%	SMA50	-3.51%	SMA200	-1.77%	Trades		Volume	1,795,601	Change	-1.54%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-16-24	Reiterated	Needham	Buy	$46 → $62
Jul-12-24	Initiated	Barclays	Overweight	$52
Jul-08-24	Initiated	Jefferies	Buy	$63
Apr-12-24	Reiterated	Needham	Buy	$36 → $46
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy	$36 → $48
Mar-11-24	Initiated	Piper Sandler	Overweight	$43
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy	$31 → $34
Jan-04-24	Initiated	Wedbush	Outperform	$41
Nov-16-23	Initiated	Raymond James	Outperform	$30
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight	$32 → $38
Dec-14-22	Initiated	Needham	Buy	$31
Oct-21-22	Initiated	Oppenheimer	Outperform	$30
May-20-22	Initiated	BofA Securities	Neutral	$24
Mar-01-22	Upgrade	Stifel	Hold → Buy	$36 → $26
Sep-23-21	Initiated	Stifel	Hold	$34
Aug-12-21	Downgrade	Goldman	Buy → Neutral	$49 → $27
May-18-21	Initiated	Goldman	Buy	$49
May-21-20	Initiated	H.C. Wainwright	Buy	$55
Mar-09-20	Initiated	JP Morgan	Neutral	$32
Mar-09-20	Initiated	Guggenheim	Buy	$50

Show Previous Ratings

Jan-29-25 04:05PM	Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire) +5.25%
Jan-06-25 04:05PM	Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-24 04:05PM	Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-04-24 06:51AM	Revolution Medicines price target raised to $87 from $82 at Guggenheim (TipRanks)
Dec-03-24 10:38PM	Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -6.89%
04:31PM	Loading…
Dec-02-24 04:31PM	Revolution Medicines Announces Commencement of Public Offering of Common Stock (GlobeNewswire) -10.46%
07:30AM	Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio (GlobeNewswire)
Nov-27-24 04:05PM	Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024 (GlobeNewswire)
Nov-06-24 04:02PM	Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-05-24 09:00AM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-24 04:05PM	Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 (GlobeNewswire) +5.94%
Oct-25-24 04:15AM	Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Oct-23-24 06:00AM	Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Oct-21-24 04:05PM	Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) -5.31%
Oct-07-24 09:00AM	Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast (GlobeNewswire)
04:05PM	Loading…
Aug-07-24 04:05PM	Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
Jul-31-24 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024 (GlobeNewswire)
Jul-11-24 12:00PM	Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer (GlobeNewswire)
Jul-10-24 05:58AM	Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last? (Zacks)
Jul-08-24 04:05PM	Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024 (GlobeNewswire) +5.46% +10.97%
Jun-08-24 09:00AM	The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024 (InvestorPlace)
Jun-05-24 04:05PM	Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-09-24 03:41PM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 09:58PM	RVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024 (InvestorPlace)
04:02PM	Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-01-24 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024 (GlobeNewswire)
Apr-09-24 03:34PM	Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-08-24 11:36AM	Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-04-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Mar-28-24 04:05PM	Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Feb-26-24 05:20PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-20-24 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024 (GlobeNewswire)
Feb-01-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-17-24 09:55AM	Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High? (Zacks)
Jan-04-24 07:00AM	Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-09-23 09:10AM	Revolution Medicines Completes Acquisition of EQRx (GlobeNewswire) -5.48%
Nov-08-23 11:30AM	Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition (GlobeNewswire)
Nov-07-23 10:14AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:55PM	Revolution Medicines Inc (RVMD) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
04:05PM	Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-01-23 07:00AM	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote FOR Proposed Acquisition of EQRx, Inc. (GlobeNewswire)
Oct-31-23 04:15PM	Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023 (GlobeNewswire) +7.90%
Oct-23-23 04:06PM	Revolution Crashes 34% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining. (Investor's Business Daily) -34.38% +14.52%
01:48PM	Rebel's Edge - October 20: $TGH, $RVMD, and Astros VS Rangers (TheStreet.com)
12:04PM	Why Revolution Medicines Stock Is Crashing Today (Motley Fool)
10:07AM	Revolution Medicines Crashes 39% On Lackluster Test Results In Cancer Treatment (Investor's Business Daily)
Oct-22-23 02:30AM	Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 (GlobeNewswire)
Oct-19-23 07:02AM	Insider Sell: COO Margaret Horn Sells 25,000 Shares of Revolution Medicines Inc (GuruFocus.com)
Oct-16-23 03:19PM	Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90 (Investor's Business Daily) +14.08%
09:45AM	Revolution Medicines, Inc. (RVMD) Soars 23.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-13-23 02:54PM	Why Shares of Revolution Medicines Were Popping on Friday (Motley Fool) +23.60%
11:50AM	Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting (GlobeNewswire)
Oct-04-23 04:05PM	Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast (GlobeNewswire)
Sep-20-23 07:01AM	Insider Sell: COO Margaret Horn Sells 7,514 Shares of Revolution Medicines Inc (RVMD) (GuruFocus.com)
Sep-19-23 07:00AM	Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor (GlobeNewswire)
Aug-17-23 04:05PM	Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins (GlobeNewswire)
Aug-09-23 02:13PM	Industry Analysts Just Made A Sizeable Upgrade To Their Revolution Medicines, Inc. (NASDAQ:RVMD) Revenue Forecasts (Simply Wall St.)
Aug-08-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Aug-03-23 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023 (GlobeNewswire)
Aug-01-23 02:34PM	EQRx sells to another Alexis Borisy biotech after multiple pivots (American City Business Journals) +20.00%
07:00AM	Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital (GlobeNewswire)
Jul-06-23 09:59AM	Revolution Medicines Insider Ups Holding During Year (Simply Wall St.)
Jun-09-23 08:29AM	We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate (Simply Wall St.)
Jun-08-23 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.69%
May-24-23 04:05PM	Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit (GlobeNewswire)
May-13-23 08:19AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Trimmed Their Revenue Forecasts By 25% (Simply Wall St.)
May-10-23 06:10AM	Revolution Medicines First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-09-23 09:40AM	Q1 2023 Revolution Medicines Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:25PM	Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-03-23 10:00AM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:55AM	Wall Street Analysts Think Revolution Medicines, Inc. (RVMD) Could Surge 27.24%: Read This Before Placing a Bet (Zacks)
May-01-23 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023 (GlobeNewswire)
10:01AM	Revolution Medicines, Inc. (RVMD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-19-23 07:15AM	Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns climbed after last week's 16% gain, institutional investors must be happy (Simply Wall St.)
Apr-13-23 04:05PM	Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference (GlobeNewswire) +7.83%
Apr-06-23 07:00AM	Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-22-23 11:29AM	Revolution Medicines (NASDAQ:RVMD investor three-year losses grow to 18% as the stock sheds US$171m this past week (Simply Wall St.)
Mar-11-23 03:27AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 04:02PM	Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.71%
Mar-02-23 09:15PM	Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock (GlobeNewswire) -11.72% +8.78%
Mar-01-23 04:17PM	Revolution Medicines Announces Commencement of Public Offering of Common Stock (GlobeNewswire)
Feb-27-23 06:25PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +9.81%
04:05PM	Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-21-23 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023 (GlobeNewswire)
Feb-02-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Revolution Medicines, Inc. (RVMD) is a Great Choice (Zacks)
07:00AM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-23-23 05:31AM	Insiders sitting comfortably on a US$376k profit after buying Revolution Medicines, Inc. (NASDAQ:RVMD) stock worth US$1.0m last year (Simply Wall St.)
Jan-12-23 03:25AM	Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength? (Zacks) +11.12%
Jan-03-23 07:00AM	Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-22 06:15AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-26-22 08:14AM	We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely (Simply Wall St.)
Dec-19-22 07:00AM	Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor (GlobeNewswire) -9.42%
Dec-08-22 06:19AM	Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration (Benzinga)
Dec-07-22 04:05PM	Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofis Termination of SHP2 Inhibitor Development and Commercialization Collaboration (GlobeNewswire)
Nov-10-22 05:48AM	Institutional owners may consider drastic measures as Revolution Medicines, Inc.'s (NASDAQ:RVMD) recent US$110m drop adds to long-term losses (Simply Wall St.) +13.34%

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cislini Jeff	General Counsel	Jan 21 '25	Sale	40.50	2,406	97,443	39,222	Jan 22 05:30 PM
JEFFREY TODD CISLINI	Officer	Jan 21 '25	Proposed Sale	40.29	2,406	96,938		Jan 21 04:20 PM
GOLDSMITH MARK A	See Remarks	Dec 18 '24	Option Exercise	0.49	30,846	15,115	355,902	Dec 20 04:50 PM
Horn Margaret A	Chief Operating Officer	Dec 16 '24	Sale	45.40	4,329	196,553	127,991	Dec 18 04:09 PM
GOLDSMITH MARK A	See Remarks	Dec 16 '24	Sale	45.40	11,714	531,860	325,056	Dec 18 04:08 PM
Kelsey Stephen Michael	See Remarks	Dec 16 '24	Sale	45.40	4,663	211,718	259,745	Dec 18 04:07 PM
Cislini Jeff	General Counsel	Dec 16 '24	Sale	45.40	1,599	72,601	41,628	Dec 18 04:07 PM
Anders Jack	Chief Financial Officer	Dec 16 '24	Sale	45.40	2,635	119,639	96,470	Dec 18 04:06 PM
GOLDSMITH MARK A	Officer	Dec 16 '24	Proposed Sale	44.93	11,561	519,436		Dec 16 09:35 PM
Kelsey Stephen Michael	Officer	Dec 16 '24	Proposed Sale	44.93	4,604	206,858		Dec 16 08:42 PM
Cislini Jeff	Officer	Dec 16 '24	Proposed Sale	44.93	1,432	64,340		Dec 16 08:01 PM
Horn Margaret A	Officer	Dec 16 '24	Proposed Sale	44.93	4,271	191,896		Dec 16 07:39 PM
Anders Jack	Officer	Dec 16 '24	Proposed Sale	44.93	2,600	116,818		Dec 16 04:57 PM
Schroeder Thilo	Director	Dec 05 '24	Buy	46.00	1,304,347	59,999,962	2,096,612	Dec 09 04:15 PM
Cislini Jeff	General Counsel	Nov 15 '24	Sale	55.13	2,554	140,811	43,080	Nov 19 04:05 PM
JEFFREY TODD CISLINI	Officer	Nov 15 '24	Proposed Sale	57.37	2,554	146,523		Nov 15 04:44 PM
Kelsey Stephen Michael	See Remarks	Nov 13 '24	Option Exercise	4.09	16,666	68,164	281,074	Nov 15 04:08 PM
Kelsey Stephen Michael	See Remarks	Nov 13 '24	Sale	58.65	16,666	977,509	264,408	Nov 15 04:08 PM
STEPHEN M. KELSEY	Officer	Nov 13 '24	Proposed Sale	59.33	16,666	988,794		Nov 13 04:30 PM
Cislini Jeff	General Counsel	Nov 06 '24	Option Exercise	36.57	6,000	219,420	51,634	Nov 08 04:20 PM
Cislini Jeff	General Counsel	Nov 06 '24	Sale	60.00	6,000	360,000	45,634	Nov 08 04:20 PM
JEFFREY TODD CISLINI	Officer	Nov 06 '24	Proposed Sale	56.75	6,000	340,500		Nov 06 05:07 PM
GOLDSMITH MARK A	See Remarks	Nov 04 '24	Option Exercise	2.58	87,500	226,115	351,070	Nov 05 04:21 PM
GOLDSMITH MARK A	See Remarks	Nov 01 '24	Option Exercise	4.09	9,100	37,219	309,270	Nov 05 04:21 PM
GOLDSMITH MARK A	See Remarks	Nov 04 '24	Sale	55.56	50,900	2,827,821	300,170	Nov 05 04:21 PM
GOLDSMITH MARK A	See Remarks	Nov 01 '24	Sale	55.02	10,000	550,238	20,424	Nov 05 04:21 PM
GOLDSMITH MARK A	See Remarks	Nov 01 '24	Sale	55.02	9,100	500,714	300,170	Nov 05 04:21 PM
Patel Sushil	Director	Oct 31 '24	Option Exercise	24.84	5,000	124,200	24,948	Nov 04 04:05 PM
Patel Sushil	Director	Oct 31 '24	Sale	54.14	5,000	270,714	19,948	Nov 04 04:05 PM
REBECCA EVE GOLDSMITH TR U/A D	Director	Nov 01 '24	Proposed Sale	53.50	5,000	267,500		Nov 01 04:43 PM
J H GOLDSMITH & M A GOLDSMITH	Director	Nov 01 '24	Proposed Sale	53.50	5,000	267,500		Nov 01 04:42 PM
MARK A GOLDSMITH	Director	Nov 01 '24	Proposed Sale	53.50	60,000	3,210,000		Nov 01 04:42 PM
SUSHIL PATEL	Director	Oct 31 '24	Proposed Sale	50.50	5,000	252,500		Oct 31 04:30 PM
Kelsey Stephen Michael	See Remarks	Oct 14 '24	Option Exercise	4.09	16,666	68,164	281,074	Oct 16 04:07 PM
Kelsey Stephen Michael	See Remarks	Oct 14 '24	Sale	49.49	16,666	824,804	264,408	Oct 16 04:07 PM
Horn Margaret A	Chief Operating Officer	Oct 11 '24	Option Exercise	4.09	50,000	204,500	182,320	Oct 15 05:31 PM
Horn Margaret A	Chief Operating Officer	Oct 11 '24	Sale	50.34	50,000	2,517,055	132,320	Oct 15 05:31 PM
GOLDSMITH MARK A	See Remarks	Oct 11 '24	Option Exercise	4.09	30,000	122,700	330,170	Oct 15 05:30 PM
GOLDSMITH MARK A	See Remarks	Oct 11 '24	Sale	50.36	30,000	1,510,773	300,170	Oct 15 05:30 PM
Anders Jack	Chief Financial Officer	Oct 11 '24	Option Exercise	2.68	10,000	26,800	108,932	Oct 15 05:30 PM
Anders Jack	Chief Financial Officer	Oct 11 '24	Sale	50.30	10,000	502,979	98,932	Oct 15 05:30 PM
Cislini Jeff	General Counsel	Oct 11 '24	Option Exercise	36.57	6,000	219,420	51,634	Oct 15 05:29 PM
Cislini Jeff	General Counsel	Oct 11 '24	Sale	50.17	6,000	301,027	45,634	Oct 15 05:29 PM
STEPHEN M. KELSEY	Officer	Oct 14 '24	Proposed Sale	50.48	16,666	841,300		Oct 15 08:03 AM
MARK A GOLDSMITH	Director	Oct 11 '24	Proposed Sale	49.50	30,000	1,485,000		Oct 11 04:22 PM
JEFFREY TODD CISLINI	Officer	Oct 11 '24	Proposed Sale	49.50	6,000	297,000		Oct 11 04:21 PM
JACK LEE ANDERS	Officer	Oct 11 '24	Proposed Sale	49.50	10,000	495,000		Oct 11 04:21 PM
MARGARET A HORN	Officer	Oct 11 '24	Proposed Sale	49.50	50,000	2,475,000		Oct 11 04:21 PM
Weber Barbara	Director	Oct 08 '24	Sale	48.02	5,200	249,716	13,065	Oct 10 04:16 PM
BARBARA L WEBER	Director	Oct 08 '24	Proposed Sale	47.34	5,200	246,168		Oct 08 04:23 PM
GOLDSMITH MARK A	See Remarks	Oct 01 '24	Option Exercise	4.09	10,000	40,900	310,170	Oct 03 04:33 PM
GOLDSMITH MARK A	See Remarks	Oct 01 '24	Sale	44.93	10,000	449,322	300,170	Oct 03 04:33 PM
MARK A GOLDSMITH	Director	Oct 01 '24	Proposed Sale	45.35	10,000	453,500		Oct 01 04:33 PM
Anders Jack	Chief Financial Officer	Sep 16 '24	Sale	44.19	2,244	99,152	98,932	Sep 18 04:18 PM
GOLDSMITH MARK A	See Remarks	Sep 16 '24	Sale	44.19	11,715	517,631	300,170	Sep 18 04:18 PM
Horn Margaret A	Chief Operating Officer	Sep 16 '24	Sale	44.19	4,331	191,367	132,320	Sep 18 04:17 PM
Kelsey Stephen Michael	See Remarks	Sep 16 '24	Sale	44.19	4,665	206,124	264,408	Sep 18 04:17 PM
Cislini Jeff	General Counsel	Sep 16 '24	Sale	44.19	1,454	64,245	45,634	Sep 18 04:16 PM
Anders Jack	Officer	Sep 16 '24	Proposed Sale	42.12	1,832	77,164		Sep 16 07:06 PM
Kelsey Stephen Michael	Officer	Sep 16 '24	Proposed Sale	42.12	4,601	193,794		Sep 16 06:41 PM
Horn Margaret A	Officer	Sep 16 '24	Proposed Sale	42.12	4,271	179,895		Sep 16 06:22 PM
Cislini Jeff	Officer	Sep 16 '24	Proposed Sale	42.12	1,433	60,358		Sep 16 05:37 PM
Anders Jack	Officer	Sep 16 '24	Proposed Sale	42.12	1,832	77,164		Sep 16 05:24 PM
GOLDSMITH MARK A	Officer	Sep 16 '24	Proposed Sale	42.12	11,561	486,949		Sep 16 05:15 PM
Kelsey Stephen Michael	See Remarks	Sep 13 '24	Option Exercise	4.09	16,667	68,168	285,740	Sep 16 04:05 PM
Kelsey Stephen Michael	See Remarks	Sep 13 '24	Sale	43.32	16,667	722,087	269,073	Sep 16 04:05 PM
STEPHEN M. KELSEY	Officer	Sep 13 '24	Proposed Sale	41.97	16,667	699,514		Sep 13 04:23 PM
BARBARA L WEBER	Officer	Aug 21 '24	Proposed Sale	44.83	1,808	81,053		Aug 21 04:14 PM
Kelsey Stephen Michael	See Remarks	Aug 13 '24	Option Exercise	4.09	16,667	68,168	285,740	Aug 15 04:48 PM
Kelsey Stephen Michael	See Remarks	Aug 13 '24	Sale	42.98	16,667	716,389	269,073	Aug 15 04:48 PM
STEPHEN M. KELSEY	Officer	Aug 13 '24	Proposed Sale	42.98	16,667	716,348		Aug 13 04:25 PM
GOLDSMITH MARK A	See Remarks	Aug 01 '24	Option Exercise	4.09	10,000	40,900	321,885	Aug 02 05:35 PM
GOLDSMITH MARK A	See Remarks	Aug 01 '24	Sale	45.88	10,000	458,827	311,885	Aug 02 05:35 PM
MARK A GOLDSMITH	Director	Aug 01 '24	Proposed Sale	45.64	10,000	456,400		Aug 01 04:29 PM
Kelsey Stephen Michael	See Remarks	Jul 15 '24	Option Exercise	4.09	16,667	68,168	285,740	Jul 17 04:07 PM
Kelsey Stephen Michael	See Remarks	Jul 15 '24	Sale	46.47	16,667	774,516	269,073	Jul 17 04:07 PM
GOLDSMITH MARK A	See Remarks	Jul 12 '24	Option Exercise	4.09	25,000	102,250	336,885	Jul 16 05:05 PM
GOLDSMITH MARK A	See Remarks	Jul 12 '24	Sale	45.05	25,000	1,126,205	311,885	Jul 16 05:05 PM
GOLDSMITH MARK A	See Remarks	Jul 12 '24	Sale	45.01	10,000	450,117	25,424	Jul 16 05:05 PM
Cislini Jeff	General Counsel	Jul 09 '24	Sale	40.83	2,399	97,951	47,088	Jul 10 04:36 PM
Patel Sushil	Director	Jul 09 '24	Option Exercise	16.80	2,155	36,204	22,103	Jul 10 04:36 PM
Patel Sushil	Director	Jul 09 '24	Sale	44.00	2,155	94,820	19,948	Jul 10 04:36 PM
Cislini Jeff	General Counsel	Jun 26 '24	Sale	38.47	2,000	76,940	49,487	Jun 27 06:48 PM
Kelsey Stephen Michael	See Remarks	Jun 25 '24	Option Exercise	4.09	16,467	67,350	285,540	Jun 26 04:26 PM
Kelsey Stephen Michael	See Remarks	Jun 24 '24	Option Exercise	4.09	200	818	269,273	Jun 26 04:26 PM
Kelsey Stephen Michael	See Remarks	Jun 25 '24	Sale	39.06	16,467	643,152	269,073	Jun 26 04:26 PM
Kelsey Stephen Michael	See Remarks	Jun 24 '24	Sale	39.00	200	7,800	269,073	Jun 26 04:26 PM
GOLDSMITH MARK A	See Remarks	Jun 17 '24	Sale	37.39	11,950	446,770	311,885	Jun 20 04:14 PM
Anders Jack	Chief Financial Officer	Jun 17 '24	Sale	37.39	1,893	70,775	101,176	Jun 20 04:13 PM
Horn Margaret A	Chief Operating Officer	Jun 17 '24	Sale	37.39	4,415	165,064	136,651	Jun 20 04:12 PM
Kelsey Stephen Michael	See Remarks	Jun 17 '24	Sale	37.39	3,349	125,209	269,073	Jun 20 04:11 PM
Cislini Jeff	General Counsel	Jun 17 '24	Sale	37.39	1,757	65,690	51,487	Jun 20 04:11 PM
Wei Lin	Chief Medical Officer	Jun 17 '24	Sale	37.39	5,589	208,954	70,851	Jun 20 04:10 PM
GOLDSMITH MARK A	See Remarks	Jun 03 '24	Option Exercise	4.09	7,500	30,675	329,822	Jun 05 04:18 PM
GOLDSMITH MARK A	See Remarks	Jun 03 '24	Sale	39.99	7,500	299,942	322,322	Jun 05 04:18 PM
Cislini Jeff	General Counsel	May 21 '24	Sale	39.11	1,500	58,671	52,874	May 22 04:11 PM
Anders Jack	Chief Financial Officer	May 03 '24	Option Exercise	2.68	10,000	26,800	111,959	May 03 07:36 PM
Anders Jack	Chief Financial Officer	May 03 '24	Sale	40.03	10,000	400,260	101,959	May 03 07:36 PM
GOLDSMITH MARK A	See Remarks	Apr 10 '24	Sale	35.33	10,000	353,346	30,424	Apr 12 08:08 PM
GOLDSMITH MARK A	See Remarks	Apr 10 '24	Sale	35.48	7,500	266,122	452,879	Apr 12 08:08 PM

REPL

Replimune Group Inc

RVMD

Revolution Medicines Inc

Upgrade your FINVIZ experience